IRIS
MILANI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.797
AS - Asia 3.205
EU - Europa 2.350
SA - Sud America 488
Continente sconosciuto - Info sul continente non disponibili 259
AF - Africa 185
OC - Oceania 6
Totale 11.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.652
CN - Cina 1.105
SG - Singapore 855
IE - Irlanda 665
HK - Hong Kong 432
VN - Vietnam 369
BR - Brasile 354
RU - Federazione Russa 326
IT - Italia 270
DE - Germania 268
FI - Finlandia 215
FR - Francia 165
ZA - Sudafrica 129
GB - Regno Unito 109
IN - India 104
BD - Bangladesh 85
CA - Canada 75
SE - Svezia 64
UA - Ucraina 60
JP - Giappone 38
AR - Argentina 37
MX - Messico 37
PL - Polonia 36
ES - Italia 32
IQ - Iraq 30
NL - Olanda 26
TR - Turchia 26
AT - Austria 24
CO - Colombia 24
PK - Pakistan 22
ID - Indonesia 19
SA - Arabia Saudita 17
EC - Ecuador 16
VE - Venezuela 16
CL - Cile 15
MA - Marocco 13
AL - Albania 12
LT - Lituania 12
PH - Filippine 12
BE - Belgio 10
EG - Egitto 10
GR - Grecia 9
UZ - Uzbekistan 9
IR - Iran 8
MY - Malesia 8
PY - Paraguay 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
AU - Australia 6
AZ - Azerbaigian 6
BO - Bolivia 6
DK - Danimarca 6
JM - Giamaica 6
PT - Portogallo 6
BG - Bulgaria 5
ET - Etiopia 5
KZ - Kazakistan 5
PE - Perù 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
LV - Lettonia 4
MU - Mauritius 4
TH - Thailandia 4
AM - Armenia 3
IL - Israele 3
KH - Cambogia 3
KR - Corea 3
LB - Libano 3
NI - Nicaragua 3
RO - Romania 3
BB - Barbados 2
BS - Bahamas 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
LU - Lussemburgo 2
MN - Mongolia 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
VG - Isole Vergini Britanniche 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
Totale 11.013
Salva come PNG Salva come JPEG
Città #
Dublin 665
San Jose 561
Chandler 522
Ashburn 477
Singapore 453
Hong Kong 419
Dallas 385
Beijing 278
Council Bluffs 195
Boardman 175
Los Angeles 148
Nanjing 143
Ho Chi Minh City 134
Helsinki 131
Lauterbourg 124
Johannesburg 121
Jacksonville 106
Princeton 98
Lawrence 93
New York 93
Hanoi 90
Medford 84
Munich 84
Wilmington 71
Pavia 65
Nanchang 60
Buffalo 54
Redondo Beach 54
Shanghai 54
Santa Clara 50
Moscow 43
Milan 41
Shenyang 39
Hebei 38
São Paulo 37
Changsha 35
Ann Arbor 34
Orem 34
Tokyo 34
Jiaxing 32
Montreal 32
Piscataway 32
Turku 32
Frankfurt am Main 28
Tianjin 28
Warsaw 28
Chicago 27
Chennai 26
Denver 26
Norwalk 26
Nuremberg 26
London 24
Da Nang 23
Columbus 21
Hangzhou 21
Houston 21
Atlanta 20
Seattle 20
Haiphong 19
Stockholm 19
San Francisco 18
Falkenstein 17
Mexico City 17
Toronto 17
Guangzhou 15
Poplar 15
Woodbridge 15
Pune 14
The Dalles 14
Washington 14
Brooklyn 13
Manchester 13
Phoenix 13
Rio de Janeiro 13
Amsterdam 12
Ankara 12
Rome 12
Baghdad 11
Boston 11
Induno Olona 11
Tirana 11
Vienna 11
Brussels 10
Brasília 9
Fairfield 9
Hyderabad 9
Zhengzhou 9
Biên Hòa 8
Cairo 8
Charlotte 8
Dhaka 8
Medellín 8
Querétaro 8
Turin 8
Athens 7
Düsseldorf 7
Marseille 7
Paris 7
Redwood City 7
Tamm 7
Totale 7.296
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 217
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 154
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 141
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 140
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 132
A patient with AL amyloidosis with negative free light chain results 129
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 129
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 126
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 125
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 125
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 123
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 121
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 121
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 119
A practical approach to the diagnosis of systemic amyloidoses 118
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
Prognostication of survival and progression to dialysis in AA amyloidosis 116
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 113
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 112
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 112
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 111
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 110
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 109
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 109
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 108
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 107
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 107
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 107
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 107
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis 106
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 105
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 104
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 103
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 103
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 103
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 102
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 99
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 98
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 96
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy 95
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 94
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 92
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 92
A case of monoclonal gammopathy of renal significance 92
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 91
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 91
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 89
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 89
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 89
Development and Validation of Staging Systems for AA Amyloidosis 86
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 86
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 86
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 85
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 85
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 84
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 84
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 82
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 80
The lung in amyloidosis 80
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts 79
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 79
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 76
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 76
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 76
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions 75
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. 75
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 75
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis 74
Attitudes about when and how to treat patients with AL amyloidosis: an international survey 73
Management of AL amyloidosis in 2020 73
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 70
HeLLePhant: A phantom mimicking non-small cell lung cancer for texture analysis in CT images 69
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 68
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 68
The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns. 68
A powerful oral triplet for AL amyloidosis 68
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 68
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 67
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 66
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 65
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 65
Predicting survival in light chain amyloidosis 65
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance 63
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis 61
Monoclonal IgM-related AL amyloidosis 60
Management of AL amyloidosis in 2020 59
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma 58
Conventional Therapy for Amyloid Light-Chain Amyloidosis 58
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients 58
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 56
Totale 9.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.043
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022408 0 2 12 0 12 6 6 33 24 21 54 238
2022/20231.570 166 141 20 87 110 135 14 83 753 11 33 17
2023/2024678 81 139 32 51 61 135 17 37 6 25 49 45
2024/20251.899 49 123 32 49 22 159 131 90 473 94 234 443
2025/20265.242 341 330 464 651 760 213 896 282 507 358 185 255
2026/2027405 217 188 0 0 0 0 0 0 0 0 0 0
Totale 11.290